Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat + Nivolumab +/- Ipilimumab in Advanced Carcinomas (BENEFIT)
NCT04315155Phase 1Withdrawn
- Sponsor
- University of Utah
- Start
- Oct 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of belinostat in Adenocarcinoma and carcinoma (2 arms), sponsored by University of Utah. Primary endpoints: Dose Limiting Toxicities and Intolerable refractory immune mediated adverse events. Planned start Oct 2020; status: withdrawn.
02
Drugs
belinostat
03
Conditions
Adenocarcinomacarcinoma
Beyond the preview
Go deeper on NCT04315155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315155.